You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
|
|---|---|
| Published in |
Journal of Hematology & Oncology, April 2014
|
| DOI | 10.1186/1756-8722-7-33 |
| Pubmed ID | |
| Authors |
Caroline S Breton, Aimable Nahimana, Dominique Aubry, Julie Macoin, Pierre Moretti, Martin Bertschinger, Samuel Hou, Michel A Duchosal, Jonathan Back |
| Abstract |
CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic potential on human B cell malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 2% |
| Denmark | 1 | 2% |
| Unknown | 47 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 27% |
| Student > Master | 8 | 16% |
| Student > Ph. D. Student | 7 | 14% |
| Student > Bachelor | 6 | 12% |
| Other | 4 | 8% |
| Other | 5 | 10% |
| Unknown | 6 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 14 | 29% |
| Medicine and Dentistry | 10 | 20% |
| Agricultural and Biological Sciences | 9 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Immunology and Microbiology | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 7 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2021.
All research outputs
#4,688,896
of 22,753,345 outputs
Outputs from Journal of Hematology & Oncology
#346
of 1,189 outputs
Outputs of similar age
#47,091
of 226,967 outputs
Outputs of similar age from Journal of Hematology & Oncology
#4
of 16 outputs
Altmetric has tracked 22,753,345 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,967 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.